A systematic review of dysgeusia induced by cancer therapies

Supportive Care in Cancer

Volumn 18, Issue 8, 2010, Pages 1081-1087

  Hovan, Allan J ^a   Williams, P Michele ^a   Stevenson Moore, Peter ^b   Wahlin, Yula B ^c   Ohrn, Kirsten E O ^d   Elting, Linda S ^e   Spijkervet, Fred K L ^f   Brennan, Michael T ^g  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UMEÅ UNIVERSITY   (Sweden)

^d DALARNA UNIVERSITY   (Sweden)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Amifostine; Cancer therapy; Dysgeusia

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; GLUCONATE ZINC; PLACEBO; RADIOACTIVE IODINE; ZINC SULFATE;

BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DIETARY INTAKE; DISEASE SEVERITY; DYSGEUSIA; HEAD AND NECK CANCER; HEALTH CARE COST; HUMAN; MULTIMODALITY CANCER THERAPY; NUTRITIONAL COUNSELING; OBSERVATIONAL STUDY; PATIENT CARE PLANNING; PATIENT EDUCATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION RESPONSE; REVIEW; SYSTEMATIC REVIEW; THYROID CANCER;

AMIFOSTINE; DYSGEUSIA; HUMANS; NEOPLASMS; PREVALENCE; QUALITY OF LIFE; ZINC SULFATE;

EID: 77956466515     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-010-0902-1     Document Type: Review

References (36)

1. Bartoshuk LM (1990) Chemosensory alterations and cancer therapies. NCI Monogr 9:179-184
2. Amossan C et al (2003) Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the SMART (simultaneous modulated accelerated radiation therapy) boost technique. Int J Oncol Biol Phys 56 (1):136-144
3. Batist G et al (2002) Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 13:1259-1263
4. Beale J et al (2003) A phase I clinical and pharmacological study of cis-diamminedichloro (2-methylpuridine) platinum II (AMD473). Br J Cancer 88:1128-1134
5. Buntzel et al (1998) Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer 6:155-160
6. Denis et al (2003) Late toxicity results of the gortec 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys 55 (1):93-98
7. Epstein J et al (2001) Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head and Neck 23:389-398
8. Fu-Min F et al (2005) Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. Oncology 68:405-413
9. Fu-Min F et al (2004) Changes in quality of life of head-and-neck cancer patients following postoperative radiotherapy. Acta Oncol 43 (6):571-578
10. Febbo PG et al (2005) Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 (14):5233-5240
11. Hainsworth J et al (2002) Induction paclitaxel, carboplatin and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally-advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 8:311-321
12. Halyard et al (2007) Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 67 (5):1318-1322
13. Halyard M (2009) Taste and smell alterations in cancer patients-real problems with few solutions. J Support Oncol 7 (2):68-69
14. Heckmann SM et al (2005) Zinc gluconate in the treatment of dysgeusia-a randomized clinical trial. J Dent Res 84 (1):35-38
15. Hong JH et al (2009) Taste and odor abnormalities in cancer patients. J Support Oncol 7 (2):58-65
16. Huang et al (2000) Symptom profile of nasopharyngeal cancer patients during radiation therapy. Cancer Pract 8 (6):274-281
17. Hughes PJ et al (2000) Dysphagia in treated nasopharyngeal cancer. Head Neck 22:393-397
18. Just et al (2005) Confocal microscopy of the peripheral gustatory system: comparison between healthy subjects and patients suffering from taste disorders during radiochemotherapy. Laryngoscope 115:2178-2182
19. Kearvell et al (2004) Acute radiation toxicity assessment of a 3-D conformal head and neck radiation treatment technique. Australas Radiol 48:358-363
20. Kita T et al (2004) Multifactorial analysis on the short-term side-effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med 18 (4):345-349
21. Komaki et al (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable nonsmall-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58 (5):1369-1377
22. Lu et al (2005) Prospective phase II trial of concomitant boose radiotherapy for stage II nasopharyngeal carcinoma: an evaluation of response and toxicity. Laryngoscope 115:806-810
23. Macquart-Moulin et al (2000) High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 18 (4):754-764
24. Maisano R et al (2003) Is weekly docetaxel an active and gentle chemotherapy in treatment of metastatic breast cancer? Anticancer Res 23:1923-1930
25. Martin M et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granuloctye-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212
26. Ohrn K et al (2001) Oral status during RT and CT: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer 9:247-257
27. Ravasco P et al (2005) Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head and Neck 27:659-668 (Pubitemid 41113766)
28. Ripamonti C (1998) Taste alterations in cancer patients. J Pain Symptom Manage 16 (6):349-351
29. Rosenbluth B et al (2005) Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys 63:1419-1426
30. Steinback S et al (2009) Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 27 (11):1899-1905
31. Van Poznak C et al (2001) Oral gossypol in the treatment of patients with refractory metastatic breatst cancer: a phase I/II clinical trial. Breast Cancer Res Treat 66:239-248
32. Vosmik M et al (2006) IMRT with the use of simultaneous integrated boost in treatment of head and neck cancer: acute toxicity evaluation. Acta Med 49 (3):167-173
33. Williams et al (2004) The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum 31 (1):E16-E23
34. Winter et al (2004) Quality of life following resection, free flap reconstruction and postoperative external beam radiotherapy for squamous cell carcinoma of the base of tongue. Clin Otolaryngol 29:274-278
35. Yamashita et al (2006) Relation between acute and late irradiation impairment of four basic tastes and irradiated tongue volume in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys 66 (5):1422-1429
36. Brennan MT, Elting LS, Spijkervet F K L. Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. Support Care Cancer doi:10.1007/s00520-010-0856-3